Results 121 to 130 of about 25,067 (205)

Validation of a UPLC-MS/MS Method for Quantifying Intracellular Olaparib Levels in Resistant Ovarian Cancer Cells

Pharmaceuticals
Background: Ovarian cancer remains one of the leading causes of cancer-related mortality among women and constitutes a major unmet medical need. A common treatment-limiting factor for ovarian cancer patients is resistance to Poly(ADP-ribose) polymerase ...
Szymon W. Kmiecik, Jennifer Lewis, Jonas Schwickert, Henrik Breitenreicher, Martin R. Sprick, Jürgen Burhenne   +5 more
doaj   +1 more source

Pulmonary Embolism Associated with Olaparib in BRCA2-Mutated Prostate Cancer: A Case Report

Current Oncology
Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor approved for treating metastatic castration-resistant prostate cancer (mCRPC) with BRCA mutations, has significant clinical benefits.
Shuhei Ishii, Shigekatsu Maekawa, Fumiko Amano, Daichi Kikuchi, Daiki Ikarashi, Renpei Kato, Mitsugu Kanehira, Ryo Takata, Jun Sugimura, Wataru Obara   +9 more
doaj   +1 more source

Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas

Occurrence of resistance to olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) approved in ovarian carcinoma, has already been shown in clinical settings.
Marco Bolis, Giovanna Damia, Maya Ridinger, Carmen Ghilardi, Simone Canesi, Massimo Zucchetti, Divora Yemane, Luca Guarrera, Eugenio Scanziani, Ilaria Mengoli, Maria C. Barbera, Alessandra Decio, Robert Fruscio, Ilaria Craparotta, Tommaso Ceruti, Federica Guffanti, Micheal B. Yaffe, Michela Chiappa, Chiara Grasselli, Anju Karki, Jesse C. Patterson, Robin A. Lu   +21 more
core   +1 more source

Real‐World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1‐2 Pathogenic Variants

Cancer Medicine
Introduction Pancreatic cancer arising in the context of BRCA predisposition may benefit from poly(ADP‐ribose) polymerase inhibitors. We analyzed real‐world data on the impact of olaparib on survival in metastatic pancreatic cancer patients harboring ...
Michele Milella, Giulia Orsi, Mariacristina diMarco, Lisa Salvatore, Letizia Procaccio, Silvia Noventa, Silvia Bozzarelli, Ingrid Garajova, Enrico Vasile, Guido Giordano, Marina Macchini, Alessandro Cavaliere, Marina Gaule, Francesca Bergamo, Marta Chiaravalli, Andrea Palloni, Riccardo Carloni, Alessandro Bittoni, Monica Niger, Ilario Giovanni Rapposelli, Maria Grazia Rodriquenz, Mario Scartozzi, Stefania Mosconi, Elisa Giommoni, Ilaria Bernardini, Chiara Paratore, Andrea Spallanzani, Katia Bencardino, Laura Forti, Emiliano Tamburini, Sara Lonardi, Aldo Scarpa, Stefano Cascinu, Giampaolo Tortora, Isabella Sperduti, Michele Reni   +35 more
doaj   +1 more source

Lynparza (olaparib): novo tarčno zdravilo pri raku jajčnikov

, 2016
A new medicine for targeted treatment of patients with recurring serous ovarian or primary peritoneal serous carcinoma (PPSC), who have a mutation of BRCA1/2 genes (somatic mutation), was recently registered in the EU – LynparzaTM (olaparib).
Krajc, Mateja, Škof, Erik
core  

Niraparib en el tratamiento del cáncer de ovario. Eficacia y seguridad relativas de niraparib y olaparib: comparaciones indirectas.

, 2018
Se evalúa la eficacia y seguridad de niraparib como tratamiento para el cáncer de ovario epitelial seroso, de las trompas de Falopio o peritoneal primario, de alto grado, recidivado, sensible al platino, a través de una revisión rápida y una comparación ...
Alfaro Lara, Eva R.
core  

Pharmacokinetic boosting of olaparib to improve exposure, tolerance and cost-effectiveness part A

Item does not contain fulltextBackground: Pharmacokinetic (PK) boosting is the intentional use of a drug-drug interaction to enhance systemic drug exposure.
Mohmaed Ali, M.I., Koolen, S.L.W., Overbeek, J.K., Heine, R. ter, Ottevanger, P.B., Bloemendal, H.J., Erp, N. van, Guchelaar, N.A.D.   +7 more
core   +1 more source

Lynparza (olaparib) : New Mmedicine for targeted therapy of ovarian cancer

, 2018
A new medicine for targeted treatment of patients with recurring serous ovarian or primary peritoneal serous carcinoma (PPSC), who have a mutation of BRCA1/2 genes (somatic mutation), was recently registered in the EU – LynparzaTM (olaparib).
Krajc, Mateja, Škof, Erik
core  

Dual PARP/Tankyrase Inhibition Enhances Antitumor Efficacy in PTEN-Deficient Endometrial Cancer. [PDF]

J Cell Mol Med
Kang SW, Eum H, Lee JY, Lee MS, Kim YM, Kim TW, Lee SW.   +6 more
europepmc   +1 more source

Efficacy and safety of PARP inhibitor maintenance therapy in elderly ovarian cancer patients: a real-world single-center retrospective cohort study. [PDF]

Front Oncol
Lu J, Song X, Zhang C, Zhu Y, Yang H, Li Y.   +5 more
europepmc   +1 more source